MEC Plus Full List ViewBy pinki@katapult.biz / February 16, 2025 MEC Plus Speciality — Amyotrophic Lateral Sclerosis (ALS) Biomarkers Biosimilars Bladder Blood Bone Brain Breast Cancer Central Nervous System (CNS) Clinical Trials Colon Colorectal Diversity, Equity & Inclusion Featured Content Gastrointestinal Genitourinary Genomic Geriatric Gynecology Head and Neck Hematologic Hematologic Maglinencies Hematology Immunotherapy Interventional Radiology Kidney Leukemia Liquid Biopsy Liver Lung Lymphoma Malignant Malignencies Melanoma Myelodysplastic Syndrome Myeloma Neuroendocrine Novel Oral & Maxillofacial Surgery Oral Cancer Ovarian Pancreas Pancreatic Pharmacological Prostate Radiation Radiology Renal Sarcoma Skin Solid Tumor Supportive & Palliative Care Survivorship Telemedicine Thoracic Thrombosis Thymic Thyroid Urothelial Author / Speaker Title Type of Media — Video Document Audio 2024 Events — 2024 California Cancer Consortium Conference (CCC) 2024 MCM 2024 MCM 2024 MLS Cleveland 2024 MLS Nashville 2024 MLS New Orleans 2024 MLS Seattle 2024 New Orleans Summer Cancer Meeting (NOSCM) 2024 PRIMO 2024 SPS Puerto Rico 2024 SPS Seattle 2024 SPECTRUM 2024 Sylvester APP Oncology Symposium 2024 WCS 2024 MaTOS Lungs 2025 PRIMO Clear « 1 … 101 102 103 104 105 … 115 » Case Presentation - Lung - Immunotherapy Toxicity Case, How to Manage and Whether toPermanently Stop or Not Helen Shih View PDF Immunotherapy selection in mRCC Sandy Srinivas. MD View PDF Small Cell Lung Cancer - 2 New IO Regimens as Standard of Care J. Marie Suga, MD View PDF Triple-negative and Hereditary Breast Cancer Melinda Telli, M.D. View PDF Managing Toxicities from TKI EGFR and ALK Inhibitors Jane Arboleda, APRN View PDF Managing Toxicities from B-RAF and MEKInhibitors Alba Baglietto, RN, BSN View PDF B-Cell Lymphomas including Hodgkin’s Disease William Caceres-Perkins, MD, FACP View PDF CDK4-6 and PIK3CA Inhibitors in Breast Cancer Management Richard S. Finn, MD View PDF The Role of Immunotherapy in Breast Cancer Richard S. Finn, MD View PDF Current Status of Biosimilars and Recent Approvals Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE View PDF Immunologic Therapy for Melanoma Geoffrey T. Gibney, MD View PDF Frontline Therapy in Myeloma - How to Decide the Best Approach Sergio Giralt, MD View PDF Immunotherapy in Gastrointestinal Tumors (CRC, Esophageal, and other) Axel Grothey, MD View PDF Predictive and Prognostic BiomarkersUsing Genomic Profile in Adjuvant Breast Cancer D. Constanza Guaqueta, MD View PDF Handling the Most Common Toxicities fromIO - Endocrinopathies, Pneumonitis, SkinRash-Pruritus, and Adrenal Insufficiency Jeanelle King, PA-C View PDF Kidney and Bladder Cancers as Targets for Immunotherapy Alan J. Koletsky, MD View PDF Managing Expectations-Goals of Care & Family Support Mayra A. Lima, ARNP, MSN, FNP-C View PDF Immunotherapy in Head and Neck Cancer Raja Mudad, MD, FACP View PDF Chronic Lymphocytic Leukemia - Frontline & Relapsed Disease Javier Pinilla-Ibarz, MD, PhD View PDF NTRK, Exon 20 insertions, and Potential Novel Pathways in Lung Cancer Luis E. Raez, MD View PDF HER-2 Disease - Neo-, Adjuvant,Metastatic Setting Noridza Rivera-Rodriguez, MD View PDF Pancreas and Hepatobiliary Tract Caio Max S. Rocha Lima, MD View PDF RET, MET, and BRAF Mutant Lung Cancer Tumors Edgardo S. Santos, MD, FACP View PDF Lung Cancer Immunotherapy Pedro G. Solivan, MD View PDF Novel Approaches for Early Stages-Locally Advanced Esophageal and GE Junction Tumors Pedro G. Solivan, MD View PDF
